ASB9

Summary

ASB9 (ankyrin repeat and SOCS box containing 9, HGNC:17184) is a protein-coding gene on chromosome Xp22.2, encoding Ankyrin repeat and SOCS box protein 9 (Q96DX5). Substrate-recognition component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex, also named CRL5 complex), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

This gene encodes a member of the ankyrin repeat and suppressor of cytokine signaling (SOCS) box protein family. Members of this family can interact with the elongin B-C adapter complex via their SOCS box domain and further complex with the cullin and ring box proteins to form E3 ubiquitin ligase complexes. They may function to mediate the substrate-recognition of the E3 ubiquitin ligases. A transcribed pseudogene of this gene has been identified on chromosome 15. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 140462 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 98 total — 1 pathogenic
• MANE Select transcript: NM_001031739

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17184
Approved symbol	ASB9
Name	ankyrin repeat and SOCS box containing 9
Location	Xp22.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZP564L0862, MGC4954, FLJ20636
Ensembl gene	ENSG00000102048
Ensembl biotype	protein_coding
OMIM	300890
Entrez	140462

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 11 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000380483, ENST00000380485, ENST00000380488, ENST00000470015, ENST00000473862, ENST00000477346, ENST00000481384, ENST00000484017, ENST00000546332, ENST00000904610, ENST00000904611, ENST00000904612, ENST00000904613, ENST00000904614, ENST00000904615

RefSeq mRNA: 4 — MANE Select: NM_001031739 NM_001031739, NM_001168530, NM_001168531, NM_024087

CCDS: CCDS14163, CCDS35208, CCDS55372

Canonical transcript exons

ENST00000380488 — 7 exons

Exon	Start	End
ENSE00001485138	15269781	15270083
ENSE00003475135	15252254	15252404
ENSE00003480596	15250430	15250564
ENSE00003483994	15254737	15254844
ENSE00003633957	15258866	15258945
ENSE00003639299	15243987	15244630
ENSE00003656261	15248744	15248935

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 89.73.

FANTOM5 (CAGE): breadth broad, TPM avg 0.4369 / max 19.6022, expressed in 226 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
198517	0.3991	216
198516	0.0378	17

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.73	gold quality
islet of Langerhans	UBERON:0000006	89.58	gold quality
right testis	UBERON:0004534	89.55	gold quality
left testis	UBERON:0004533	88.31	gold quality
nephron tubule	UBERON:0001231	88.26	gold quality
testis	UBERON:0000473	87.93	gold quality
adult organism	UBERON:0007023	84.47	gold quality
kidney epithelium	UBERON:0004819	82.28	gold quality
renal glomerulus	UBERON:0000074	80.93	gold quality
metanephric glomerulus	UBERON:0004736	80.17	gold quality
right lobe of liver	UBERON:0001114	80.00	gold quality
spleen	UBERON:0002106	79.33	gold quality
pancreas	UBERON:0001264	78.91	gold quality
cortex of kidney	UBERON:0001225	78.58	gold quality
adult mammalian kidney	UBERON:0000082	77.57	gold quality
kidney	UBERON:0002113	76.80	gold quality
liver	UBERON:0002107	76.79	gold quality
metanephros	UBERON:0000081	76.07	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.84	gold quality
body of pancreas	UBERON:0001150	75.44	gold quality
bronchial epithelial cell	CL:0002328	72.24	gold quality
metanephros cortex	UBERON:0010533	70.65	gold quality
rectum	UBERON:0001052	70.44	gold quality
minor salivary gland	UBERON:0001830	70.31	gold quality
body of stomach	UBERON:0001161	69.79	gold quality
gall bladder	UBERON:0002110	69.14	gold quality
upper lobe of left lung	UBERON:0008952	68.89	gold quality
visceral pleura	UBERON:0002401	68.84	gold quality
smooth muscle tissue	UBERON:0001135	68.69	gold quality
epithelium of bronchus	UBERON:0002031	68.59	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-81547	yes	16.67
E-MTAB-6678	no	2.41
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting ASB9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-569	99.42	66.32	1009
HSA-MIR-4721	99.26	66.05	818
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-4763-5P	98.75	63.89	854
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-224-5P	98.33	70.12	1256
HSA-MIR-5585-3P	98.25	67.41	941
HSA-MIR-649	97.96	67.21	704
HSA-MIR-3129-3P	97.85	67.63	1246
HSA-MIR-5583-5P	97.85	67.61	1243
HSA-MIR-3616-3P	96.96	65.45	983
HSA-MIR-514A-5P	96.94	65.49	801
HSA-MIR-664B-5P	96.74	67.50	509

Literature-anchored findings (GeneRIF, showing 10)

• The splice variant of hASB9, hASB9-2 protein, was cloned, overexpressed, and crystallized and the data showed that the cubic hASB9-2 crystal belongs to space group P4(3)32 with unit-cell parameters. (PMID:18680464)
• The purified ASB9-2 protein, the splice variant of ASB9 with only one ankyrin repeat domain, was crystallized and diffracted to 2.2A resolution. (PMID:19275750)
• ASB9 interacts with the creatine kinase system and negatively regulates cell growth. (PMID:20302626)
• The results of the present study suggest that ASB9 is a useful prognostic marker for colorectal cancer (PMID:20878058)
• His103 and Phe107 in hASB9-2 are essential for binding to CKB. (PMID:22418839)
• ASB9 is unstable alone but forms a stable ternary complex with EloBC that binds with high affinity to the Cullin 5 N-terminal domain. (PMID:23837592)
• Molecular docking yielded a structural model consistent with all of the data that suggested the N-terminal residues of ASB9(1-252) may lie in one CK active site. This model was corroborated by enzymatic activity assays and mutational analysis. (PMID:25654263)
• Model of ASB9 in complex with its substrate, creatine kinase, reveals a mechanism for dynamic ubiquitin transfer. (PMID:27396830)
• Structure and dynamics of the ASB9 CUL-RING E3 Ligase. (PMID:32513959)
• Ubiquitin protein E3 ligase ASB9 suppresses proliferation and promotes apoptosis in human spermatogonial stem cell line by inducing HIF1AN degradation. (PMID:36683111)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Asb9	ENSMUSG00000031384
rattus_norvegicus	Asb9	ENSRNOG00000067365

Paralogs (2): ASB5 (ENSG00000164122), ASB11 (ENSG00000165192)

Protein

Protein identifiers

Ankyrin repeat and SOCS box protein 9 — Q96DX5 (reviewed: Q96DX5)

All UniProt accessions (3): Q96DX5, A0A024RBW7, R4GN94

UniProt curated annotations — full annotation on UniProt →

Function. Substrate-recognition component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex, also named CRL5 complex), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. The ECS(ASB9) complex catalyzes ubiquitination of creatine kinases CKB and CKMT1A. Does not interact with the Elongin BC complex, likely to be a negative regulator of isoform 1.

Subunit / interactions. Substrate-recognition component of the ECS(ASB9) complex, composed of ASB9, CUL5, ELOB, ELOC and RNF7/RBX2.

Subcellular location. Mitochondrion.

Tissue specificity. Predominantly expressed in testis, kidney, and liver.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the ankyrin SOCS box (ASB) family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96DX5-1	1	yes
Q96DX5-2	2, ASB9deltaSOCS
Q96DX5-3	3

RefSeq proteins (4): NP_001026909, NP_001162002, NP_001162003, NP_076992 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001496	SOCS_box	Domain
IPR002110	Ankyrin_rpt	Repeat
IPR036036	SOCS_box-like_dom_sf	Homologous_superfamily
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR037333	ASB9/11_SOCS	Domain
IPR051573	Ankyrin-SOCS_box_domain	Family

Pfam: PF07525, PF12796

UniProt features (38 total): helix 17, repeat 6, strand 3, modified residue 2, splice variant 2, sequence conflict 2, site 2, chain 1, mutagenesis site 1, turn 1, domain 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
3D9H	X-RAY DIFFRACTION	2.2
3ZKJ	X-RAY DIFFRACTION	2.58
3ZNG	X-RAY DIFFRACTION	2.85
6V9H	ELECTRON MICROSCOPY	4.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DX5-F1	91.89	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 103 (essential for binding to ckb); 107 (essential for binding to ckb)

Post-translational modifications (2): 1, 51

Mutagenesis-validated functional residues (1):

Position	Phenotype
32	decreased ability to mediate ubiquitination of ckb.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 106 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOZGIT_ESR1_TARGETS_DN, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, WEI_MYCN_TARGETS_WITH_E_BOX, ONKEN_UVEAL_MELANOMA_UP, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, BLALOCK_ALZHEIMERS_DISEASE_UP, TGCTGAY_UNKNOWN, GOBP_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS

GO Biological Process (4): protein ubiquitination (GO:0016567), intracellular signal transduction (GO:0035556), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), positive regulation of protein catabolic process (GO:0045732)

GO Molecular Function (2): ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (3): mitochondrion (GO:0005739), cytosol (GO:0005829), Cul5-RING ubiquitin ligase complex (GO:0031466)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Post-translational protein modification	1
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Metabolism of proteins	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
protein modification by small protein conjugation	1
intracellular anatomical structure	1
signal transduction	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
positive regulation of catabolic process	1
protein catabolic process	1
regulation of protein catabolic process	1
positive regulation of protein metabolic process	1
enzyme-substrate adaptor activity	1
binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

1460 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ASB9	ELOC	Q15369	825
ASB9	CKB	P12277	725
ASB9	ELOB	Q15370	718
ASB9	CUL5	Q93034	717
ASB9	CKMT1B	P12532	678
ASB9	SOCS4	Q8WXH5	604
ASB9	SOCS6	O14544	593
ASB9	MOSPD2	Q8NHP6	504
ASB9	TMEM272	A0A1B0GTI8	482
ASB9	RNF7	Q9UBF6	470
ASB9	ASB17	Q8WXJ9	470
ASB9	ASB6	Q9NWX5	469
ASB9	CRIP1	P50238	448
ASB9	RELT	Q969Z4	447
ASB9	CISH	Q9NSE2	445

IntAct

89 interactions, top by confidence:

A	B	Type	Score
CKB	ASB9	psi-mi:“MI:0915”(physical association)	0.940
ASB9	CKB	psi-mi:“MI:0915”(physical association)	0.940
CKM	ASB9	psi-mi:“MI:0915”(physical association)	0.870
ASB9	CKM	psi-mi:“MI:0915”(physical association)	0.870
ASB9	HIF1AN	psi-mi:“MI:0915”(physical association)	0.870
ASB9	CKM	psi-mi:“MI:0914”(association)	0.870
HIF1AN	ASB9	psi-mi:“MI:0915”(physical association)	0.870
CDK2	CCNB2	psi-mi:“MI:0914”(association)	0.860
CKMT1A	ASB9	psi-mi:“MI:0915”(physical association)	0.740
ELOC	ASB9	psi-mi:“MI:0915”(physical association)	0.740
HEL-S-29	ASB9	psi-mi:“MI:0915”(physical association)	0.560
EXOSC1	ASB9	psi-mi:“MI:0915”(physical association)	0.560
ASB13	ASB9	psi-mi:“MI:0915”(physical association)	0.560
RELA	ASB9	psi-mi:“MI:0915”(physical association)	0.560
ACTN3	ASB9	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (119): ASB9 (Two-hybrid), ASB9 (Two-hybrid), UBB (Affinity Capture-MS), TCEB1 (Affinity Capture-MS), CUL5 (Affinity Capture-MS), CKM (Affinity Capture-MS), CKB (Affinity Capture-MS), CKMT1A (Affinity Capture-MS), HIF1AN (Affinity Capture-MS), ARIH2 (Affinity Capture-MS), ASB9 (Two-hybrid), ASB9 (Two-hybrid), ASB9 (Two-hybrid), ASB9 (Two-hybrid), CRK (Affinity Capture-Luminescence)

ESM2 similar proteins: A2AS55, B2RXR6, O15084, O75832, P0C927, Q08DV6, Q0P5B9, Q29RM5, Q2TB02, Q3SX45, Q495B1, Q499M5, Q4V890, Q502K3, Q505D1, Q53RE8, Q5F478, Q5RFS1, Q5U2S6, Q5ZLC8, Q6GPE5, Q6P6B7, Q6P9Z4, Q70X92, Q7T3P8, Q810B6, Q8BTI7, Q8C0T1, Q8C6Y6, Q8K0L0, Q8N8A2, Q8NB46, Q8NI38, Q8WXH4, Q91ZT8, Q96AX9, Q96DX5, Q96NS5, Q96Q27, Q9BSK4

Diamond homologs: A0A072VIM5, A0A0K0PU92, A2CIR7, B9DHT4, C9JJ37, E7BQV0, G3LSH3, G8GTN7, Q05823, Q0JJ01, Q2HW56, Q2QXZ2, Q2RAQ5, Q5D0W8, Q5ICL9, Q5XIU1, Q75HA6, Q8L746, Q96BM1, Q96DX5, Q99LJ2, Q9FDY4, Q9M1I7, Q9SZI3, Q9ZVC2, S4VGD0, A6QPA3, B7U179, Q5R4S6, Q8R179, Q9N010, Q9NVX7, Q6NYM1, Q9LXV4, Q02989, Q17QS6, Q3SZE4, Q5RFS1, Q70X92, Q810B6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ASB9	“down-regulates quantity by destabilization”	CKB	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

98 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	23
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3245767	NC_000023.10:g.(?14027032)(19854400_?)del	Pathogenic

SpliceAI

871 predictions. Top by Δscore:

Variant	Effect	Δscore
X:15248725:G:C	donor_gain	1.0000
X:15248936:C:CC	acceptor_gain	1.0000
X:15250573:C:CT	acceptor_gain	1.0000
X:15250573:C:T	acceptor_gain	1.0000
X:15250574:A:T	acceptor_gain	1.0000
X:15248746:T:A	donor_gain	0.9900
X:15248752:T:A	donor_gain	0.9900
X:15248808:G:A	donor_gain	0.9900
X:15248931:CGCTC:C	acceptor_gain	0.9900
X:15248933:CTC:C	acceptor_gain	0.9900
X:15248942:A:T	acceptor_gain	0.9900
X:15248945:C:CT	acceptor_gain	0.9900
X:15248947:C:CT	acceptor_gain	0.9900
X:15250424:CTTTA:C	donor_loss	0.9900
X:15250427:TACCT:T	donor_loss	0.9900
X:15250428:A:G	donor_loss	0.9900
X:15250429:CC:C	donor_loss	0.9900
X:15250565:C:CC	acceptor_gain	0.9900
X:15250566:T:A	acceptor_loss	0.9900
X:15250578:C:CT	acceptor_gain	0.9900
X:15250579:A:T	acceptor_gain	0.9900
X:15252421:C:CT	acceptor_gain	0.9900
X:15254840:CACCC:C	acceptor_gain	0.9900
X:15254842:CCC:C	acceptor_gain	0.9900
X:15254843:CCC:C	acceptor_gain	0.9900
X:15269779:ACCG:A	donor_gain	0.9900
X:15269779:ACCGC:A	donor_gain	0.9900
X:15269780:CCG:C	donor_gain	0.9900
X:15269780:CCGC:C	donor_gain	0.9900
X:15269780:CCGCC:C	donor_gain	0.9900

AlphaMissense

1939 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:15254788:A:C	C77W	0.989
X:15254790:A:G	C77R	0.987
X:15252362:C:G	A109P	0.986
X:15252357:A:C	C110W	0.985
X:15252359:A:G	C110R	0.985
X:15254793:C:G	A76P	0.985
X:15252266:C:G	A141P	0.983
X:15254789:C:T	C77Y	0.982
X:15250441:A:G	L186P	0.980
X:15254756:A:G	L88S	0.980
X:15252358:C:T	C110Y	0.979
X:15250475:A:G	C175R	0.974
X:15258910:C:G	A44P	0.973
X:15252263:C:G	A142P	0.972
X:15252262:G:T	A142D	0.971
X:15252366:A:C	F107L	0.969
X:15252366:A:T	F107L	0.969
X:15252368:A:G	F107L	0.969
X:15258909:G:T	A44E	0.968
X:15252265:G:T	A141D	0.965
X:15250473:A:C	C175W	0.963
X:15258913:C:G	A43P	0.963
X:15250478:C:G	A174P	0.962
X:15252325:A:G	L121P	0.962
X:15250477:G:T	A174D	0.960
X:15254801:A:T	L73H	0.960
X:15252361:G:T	A109D	0.959
X:15250474:C:T	C175Y	0.956
X:15254804:G:C	P72R	0.955
X:15258876:A:G	L55P	0.955

dbSNP variants (sampled 300 via entrez): RS1000058425 (X:15257329 C>G,T), RS1000244666 (X:15251905 G>A), RS1000358829 (X:15243691 G>A), RS1000832014 (X:15259445 A>G), RS1000871687 (X:15249527 C>T), RS1001049363 (X:15258954 A>G,T), RS1001060037 (X:15255465 G>A), RS1001072202 (X:15243500 A>G), RS1001387906 (X:15249930 G>A), RS1001462128 (X:15256404 A>C), RS1001479474 (X:15267344 G>A,C), RS1001670979 (X:15270094 A>ACC), RS1001852889 (X:15261176 A>C), RS1002050138 (X:15261082 C>T), RS1002084184 (X:15269378 T>C)

Disease associations

OMIM: gene MIM:300890 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009391_740	Metabolite levels	6.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
Benzo(a)pyrene	decreases expression, decreases methylation, affects methylation	6
Aflatoxin B1	decreases methylation, affects expression, decreases expression	5
Cyclosporine	decreases expression	3
sodium arsenite	decreases expression	2
Vorinostat	affects cotreatment, increases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
dicrotophos	decreases expression	1
apocarotenal	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	affects expression	1
trichostatin A	increases expression	1
arsenite	affects binding, increases reaction	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
ICG 001	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
MRK 003	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
NSC 689534	affects binding, decreases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Panobinostat	increases expression, affects cotreatment	1
Arsenic	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.